Cantargia is a clinical-stage biotechnology company developing antibody-based therapies targeting the interleukin-1-receptor-accessory protein (IL1RAP) for the treatment of cancer, autoimmune, and inflammatory diseases. The company's lead candidate, nadunolimab, is a humanized monoclonal antibody in Phase II clinical trials for pancreatic ductal adenocarcinoma and non-small cell lung cancer, having received FDA Fast Track Designation for the former. Cantargia's pipeline includes the bispecific antibody project CAN14 and next-generation antibody-drug conjugates. In 2025, the company entered a strategic partnership with Otsuka Pharmaceutical, which acquired the CAN10 program for the treatment of autoimmune and inflammatory conditions. Cantargia collaborates with academic institutions, including Texas MD Anderson Cancer Center and Mount Sinai Tisch Cancer Center, for investigator-initiated studies in leukemia and colorectal cancer.

Summarised from the company's own disclosures

Industry Biotechnology Homepage cantargia.com
Sector Healthcare IR page cantargia.com
Tags
oncology, pancreatic cancer, non-small cell lung cancer, autoimmune diseases, inflammatory diseases, antibody-based therapies, bispecific antibodies, antibody-drug conjugates, il1rap target, precision medicine, nadunolimab, CAN04, CAN10, CAN14, CANxx, Otsuka Pharmaceutical, TRIFOUR, CANFOUR, Texas MD Anderson Cancer Center, Mount Sinai Tisch Cancer Center
Press page —

Metrics

Valuation  
Market cap kr 1.019B
Market cap (USD) $ 100.33M
P/E 6.03
PEG —
P/BV 3.83
P/S 3.22
P/OCF 6.79
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 76.9%
ROI 55.3%
ROIC 43.5%
Profit margin 46.4%
Growth  
Revenue growing —
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 33
Quality score 58.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 316.702M 0 — — — — — — —
Net profit 146.974M -161.654M -280.027M -371.814M -366.504M -173.085M -110.809M -91.16M -60.253M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 1.55 1.8 — — — — 18.46 6.8 6.8
Price performance 12m -0.14 -0.53 — — — — 1.71 0 —

Filed figures

Figure Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (SEK) — 19.5M 131M 11.6M
↳ YoY growth +574.8% -91.2%
Other receivables (SEK) — 2.19M 122M 3.16M
Cash and deposits (SEK) 190M 140M 33M 282M
Intangible assets (SEK) — 4.66M 3.76M 2.85M
Cash flow detail
Operating cash flow (SEK) — -287M -163M 150M
Purchases of property, plant and equipment (SEK) — — 0.00 -472,000
Change in receivables (cash effect) (SEK) — 15.7M 8.25M -359,000
Change in payables (cash effect) (SEK) — -14.7M -12.2M -5.01M
Interest paid (cash effect) (SEK) — -1,000 0.00 -1.13M
Operating cash flow before change in receivables (SEK) — -302M -171M 150M
Free cash flow (OCF - PPE - intangibles) (SEK) — — -163M 150M
Income detail
Research and development expense (SEK) — 273M 154M 133M
Reported — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Cantargia AB (publ) (Nasdaq Stockholm: CANTA), ett bioteknikföretag i klinisk fas med fokus på antikroppsbaserade behandlingar riktade mot IL1RAP, meddelade idag att valberedning inför årsstämman 2027 utsetts och består av Anna Magnusson (Fjärde AP-fonden), Anna Henricsson (Handelsbanken Fonder), Henrick Schill och Magnus Persson (styrelsens ordförande). Valberedningen har utsetts i enlighet med riktlinjer fastlagda på årsstämman 2023.

Valberedningen representerar per den 30 september 2026 cirka 13 procent av aktierna i Cantargia. I enlighet med instruktionerna har Cantargia’s största ägare erbjudits att nominera en medlem. Avanza Pension, Fenja Capital Partners och American Century Investment har avstått att utse representanter. Anna Magnusson, representant för bolagets största aktieägare, kommer att vara ordförande i valberedningen.

Årsstämman kommer att äga rum den 25 maj 2027 på Ideon Gateway, Scheelevägen 27, i Lund.

Valberedningens uppgift är att inför årsstämman förbereda och framlägga förslag avseende ordförande vid årsstämman, val av ordförande och övriga ledamöter i styrelsen, styrelsearvode uppdelat mellan ordförande och övriga ledamöter samt eventuell ersättning för utskottsarbete och val av revisor samt ersättning till denne. Slutligen kommer valberedningen föreslå principer för tillsättandet av valberedningen (om valberedningen anser att gällande principer och instruktion bör uppdateras).

Aktieägare är välkomna att inkomma med förslag och synpunkter till valberedningen till Cantargia AB, att: Valberedning, Scheelevägen 27, 223 63 Lund, eller via e-post till [email protected] . För att säkerställa att förslag ska kunna behandlas av valberedningen ska dessa inkomma i god tid före stämman, dock senast den 31 januari 2027.

Valberedningens förslag kommer att presenteras i kallelsen till årsstämman och på Cantargias hemsida.

Cantargia AB (publ) (Nasdaq Stockholm: CANTA), a clinical-stage biotechnology company focused on antibody-based therapeutics targeting IL1RAP, today provided notification that the Nomination Committee (NC) has been appointed ahead of the 2027 Annual General Meeting (AGM) and consists of Anna Magnusson (Fjärde AP-fonden), Anna Henricsson (Handelsbanken Fonder), Henrick Schill, and Magnus Persson (Chairman of the Board). The NC has been appointed in accordance with the guidelines established at the 2023 AGM.

As of September 30, 2026, the Nomination Committee represents approximately 13 per cent of the shares in Cantargia. In accordance with the guideline, Cantargia's largest shareholders have been offered to nominate a member. Avanza Pension, Fenja Capital Partners and American Century Investment have refrained from appointing a representative. Anna Magnusson, representing the largest shareholder, will be the chairman of the NC.

The Annual General Meeting will be held on May 25, 2027, at Ideon Gateway, Scheelevägen 27, in Lund, Sweden.

The Nomination Committee's tasks for the AGM are to propose a Chairman for the AGM, members of the Board of Directors and Chairman of the Board of Directors, remuneration to the members and the chairman respectively and potential remuneration for committee and election of auditor, including principles of remuneration of the auditor. Finally, the NC will propose principles for appointing the Nomination Committee (if the Nomination Committee considers that the current principles and instructions should be updated).

Shareholders are welcome to submit their proposals and views to the NC to Cantargia AB, Att: Nomination Committee, Scheelevägen 27, 223 63 Lund, or by e-mail to [email protected] . To ensure that proposals can be considered by the Nomination Committee, proposals shall be submitted in due time before the Annual General Meeting and received no later than January 31, 2027.

The Nomination Committee's proposals will be announced in the notice for the AGM and on Cantargia’s web site.

Prompts

Cantargia (ticker CANTA), listed in Sweden.

ETFs Holding Cantargia

ETF Weight in ETF Shares Market value As of
AVDE 0.00% 828,224 $ 112.033K Nov 16, 2026
AVDV 0.00% 6,562,227 $ 887.662K Nov 16, 2026
AVDS 0.00% 45,519 $ 6,157.29 Nov 16, 2026